(secondQuint)Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients.

 The primary objective of this study is as follows: - To evaluate the safety and tolerability of tenofovir following administration of tenofovir disoproxil fumarate 300 mg for 48 weeks in HIV-infected patients experiencing various degrees of renal impairment.

 The secondary objectives of this study are as follows: - To evaluate the safety and tolerability of emtricitabine following administration of emtricitabine 200 mg for 48 weeks in HIV-infected patients experiencing various degrees of renal impairment.

 - To evaluate the efficacy of tenofovir disoproxil fumarate in combination with emtricitabine in renally-impaired HIV-infected patients.

 - To evaluate the pharmacokinetics of tenofovir and emtricitabine in renally-impaired HIV-infected patients.

.

 Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients@highlight

The purpose of this study is to provide long-term clinical safety and efficacy data for tenofovir disoproxil fumarate and emtricitabine in HIV-infected patients experiencing various degrees of renal impairment.

